The Heart Failure with Reduced Ejection Fraction market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Heart Failure (HF) with Reduced Ejection Fraction (HFrEF): An Overview
Heart Failure is a clinical syndrome characterized by dyspnea or exertional limitation due to impairment of ventricular filling or ejection of blood, or both. HFrEF occurs when the left ventricular ejection fraction (LVEF) is 40% or less and is accompanied by progressive left ventricular dilatation and adverse cardiac remodeling. Assessment for heart failure begins with obtaining a medical history and physical examination. Also central to diagnosis are elevated natriuretic peptides above age- and context-specific thresholds and identification of left ventricular systolic dysfunction with LVEF of 40% or less as measured by echocardiography.
Heart Failure (HF) with Reduced Ejection Fraction (HFrEF) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Heart Failure with Reduced Ejection Fraction market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Heart Failure with Reduced Ejection Fraction market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Heart Failure (HF) with Reduced Ejection Fraction (HFrEF) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
Heart Failure (HF) with Reduced Ejection Fraction (HFrEF) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Heart Failure with Reduced Ejection Fraction market or expected to be launched during the study period. The analysis covers the Heart Failure with Reduced Ejection Fraction market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers Heart Failure with Reduced Ejection Fraction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Heart Failure with Reduced Ejection Fraction Market Will Evolve and Grow by 2032 @
Heart Failure (HF) with Reduced Ejection Fraction (HFrEF) Therapeutics Analysis
There are approx. 12+ key companies developing therapies for Heart Failure (HF) with Reduced Ejection Fraction (HFrEF). Currently, Cytokinetics is leading the therapeutics market with its Heart Failure (HF) with Reduced Ejection Fraction (HFrEF) drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Heart Failure (HF) with Reduced Ejection Fraction (HFrEF) Therapeutics Market Include:
-
Asklepios Biopharmaceutical, Inc.
-
AstraZeneca
-
Bayer
-
Berlin Cures GmbH
-
Cytokinetics
-
Innolife Co., Ltd.
-
Intra-Cellular Therapies, Inc.
-
Ionis Pharmaceuticals
-
Olatec Therapeutics LLC
-
PhaseBio Pharmaceuticals Inc.
-
Salubris Biotherapeutics Inc
-
Sardocor Corp.
-
Stealth BioTherapeutics Inc.
-
Zensun Sci. & Tech. Co., Ltd.
And Many Others
Heart Failure (HF) with Reduced Ejection Fraction (HFrEF) Drugs Covered in the Report Include:
-
IONIS-AGT-LRx: Ionis Pharmaceuticals
-
Omecamtiv mecarbil: Cytokinetics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Heart failure with Reduced Ejection Fraction Competitive Intelligence Analysis
4. Heart failure with Reduced Ejection Fraction Market Overview at a Glance
5. Heart failure with Reduced Ejection Fraction Disease Background and Overview
6. Heart failure with Reduced Ejection Fraction Patient Journey
7. Heart failure with Reduced Ejection Fraction Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Heart failure with Reduced Ejection Fraction Treatment Algorithm, Current Treatment, and Medical Practices
9. Heart failure with Reduced Ejection Fraction Unmet Needs
10. Key Endpoints of Heart failure with Reduced Ejection Fraction Treatment
11. Heart failure with Reduced Ejection Fraction Marketed Products
12. Heart failure with Reduced Ejection Fraction Emerging Drugs and Latest Therapeutic Advances
13. Heart failure with Reduced Ejection Fraction Seven Major Market Analysis
14. Attribute Analysis
15. Heart failure with Reduced Ejection Fraction Market Outlook (In US, EU5, and Japan)
16. Heart failure with Reduced Ejection Fraction Access and Reimbursement Overview
17. KOL Views on the Heart failure with Reduced Ejection Fraction Market
18. Heart failure with Reduced Ejection Fraction Market Drivers
19. Heart failure with Reduced Ejection Fraction Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
Heart Failure With Reduced Ejection Fraction (HFrEF) Pipeline Insight
“Heart Failure With Reduced Ejection Fraction (HFrEF) Pipeline Insight, 2023” report provides comprehensive insights about 12+ companies and 12+ drugs in Heart Failure With Reduced Ejection Fraction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/